Capital Flow Monitor · Sponsors · CIK 2144758
AdvanCell, Inc.
245 MAIN STREET, CAMBRIDGE, MA, 02142 · +64 22 799 1300
Biotechnology · Corporation· inc. DELAWARE true 2026
Fit score
—
Offering
$315.0M
Sold
$218.3M
% sold
69.3%
Investors
41
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-16 | D ·current | 506(b) | $315.0M | $218.3M | 69.3% | 41 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Philina Lee — Executive Officer / Director, Cambridge, MA
- Aaron Pickett — Executive Officer, Cambridge, MA
- Wing Cheong Lam — Director, Cambridge, MA
- Nik Economopoulos — Director, Cambridge, MA
-
Anthony Aiudi — Director, Cambridge, MA
1 other raise
- NEUTROLIS INC. $3.5M of $10.0M · 35.0%
-
Bali Muralidhar — Director, Cambridge, MA
2 other raises
- Allotera Therapeutics, Inc. $123.3M of $163.0M · 75.6%
- SPRUCE BIOSCIENCES, INC. $50.0M of $50.0M · 100.0%
- Jamil Beg — Director, Cambridge, MA
- Christopher Gagliardi — Director, Cambridge, MA
- Andrew Adamovich — Director, Cambridge, MA
- Andrew Kay — Director, Cambridge, MA
-
Kevin Cameron — Director, Cambridge, MA
1 other raise
- Ionetix Corp / DE / $32.3M of $32.3M · 100.0%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.